Alivus Life Sciences (Formerly Glenmark Life Sciences) Allots 4,190 Shares Under ESOP
Team Finance Saathi
07/Mar/2025

What’s Covered in the Article:
- Details of equity share allotment under ESOP 2021
- Impact on the company’s paid-up share capital
- Regulatory compliance and stock exchange filings
Alivus Life Sciences Limited, previously known as Glenmark Life Sciences Limited, has announced the allotment of 4,190 equity shares of Rs. 2 each under the Glenmark Life Sciences Limited - Employee Stock Option Scheme (ESOP) 2021. The Nomination and Remuneration Committee approved this allotment in their meeting held on March 7, 2025. This move is part of the company’s ongoing strategy to incentivize and reward employees through stock options.
Impact on Paid-up Share Capital
Following the allotment of these shares, the company’s paid-up share capital has increased as follows:
- Before allotment: 12,253,286,862 equity shares of Rs. 2 each, totaling Rs. 24,50,65,724
- After allotment: 12,253,737,052 equity shares of Rs. 2 each, totaling Rs. 24,50,74,104
This allotment reflects a minor increase in the total equity base, which is part of the employee benefits scheme aimed at boosting employee engagement and retention.
Regulatory and Compliance Details
The SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 require companies to provide certain details related to ESOP allotments. In this case, the company has filed the requisite statement with the exchanges in compliance with Regulation 10(b) on July 19, 2024. The details provided to the exchanges are as follows:
- BSE Filing Number: DSC/IPO/AK/ESOP-IP/3281/2024-25
- NSE Filing Number: NSE/LIST/42891
The equity shares allotted are identical to existing shares, and there are no lock-in restrictions placed on these shares.
Details of Allotment and Share Information
- Shares allotted: 4,190
- Exercise price per share: Rs. 716
- Premium per share: Rs. 714
- Total issued share capital after this issue: Rs. 24,50,74,104
- ISIN number for shares: INE03Q201024
- Shares are identical to existing shares: Yes, they rank pari passu (equal in all respects).
Conclusion
This allotment is part of the company’s efforts to reward employees under the ESOP scheme, which is a key component of Alivus Life Sciences' compensation strategy. Investors and stakeholders will see a slight increase in the total equity shares and paid-up capital, but this move aligns with the company’s overall employee engagement and long-term growth objectives.
The Upcoming IPOs in this week and coming weeks are Super Iron Foundry, PDP Shipping & Projects.
The Closed IPOs are NAPS Global